You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines
|
|---|---|
| Published in |
Radiation Oncology, October 2013
|
| DOI | 10.1186/1748-717x-8-246 |
| Pubmed ID | |
| Authors |
Tim Lautenschlaeger, James Perry, David Peereboom, Bin Li, Ahmed Ibrahim, Alexander Huebner, Wei Meng, Julia White, Arnab Chakravarti |
| Abstract |
Brain metastasis from breast cancer poses a major clinical challenge. Integrins play a role in regulating adhesion, growth, motility, and survival, and have been shown to be critical for metastatic growth in the brain in preclinical models. Cilengitide, an αvβ3/αvβ5 integrin inhibitor, has previously been studied as an anti-cancer drug in various tumor types. Previous studies have shown additive effects of cilengitide and radiation in lung cancer and glioblastoma cell lines. The ability of cilengitide to enhance the effects of radiation was examined preclinically in the setting of breast cancer to assess its possible efficacy in the setting of brain metastasis from breast cancer. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 28% |
| Student > Master | 6 | 13% |
| Student > Bachelor | 5 | 11% |
| Researcher | 5 | 11% |
| Student > Postgraduate | 4 | 9% |
| Other | 9 | 20% |
| Unknown | 4 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 20% |
| Biochemistry, Genetics and Molecular Biology | 9 | 20% |
| Medicine and Dentistry | 8 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Immunology and Microbiology | 2 | 4% |
| Other | 7 | 15% |
| Unknown | 8 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2013.
All research outputs
#13,161,766
of 22,727,570 outputs
Outputs from Radiation Oncology
#598
of 2,046 outputs
Outputs of similar age
#109,528
of 212,101 outputs
Outputs of similar age from Radiation Oncology
#21
of 66 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,046 research outputs from this source. They receive a mean Attention Score of 2.7. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,101 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.